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Abstract Activation of 5-HT4 receptors in failing ventricles
elicits a cAMP-dependent positive inotropic response which
is mainly limited by the cGMP-inhibitable phosphodiesterase
(PDE) 3. However, PDE4 plays an additional role which is
demasked by PDE3 inhibition. The objective of this study
was to evaluate the effect of cGMP generated by particulate
and soluble guanylyl cyclase (GC) on the 5-HT4-mediated
inotropic response. Extensive myocardial infarctions were
induced by coronary artery ligation in Wistar rats, exhibiting
heart failure 6 weeks after surgery. Contractility was
measured in left ventricular preparations. Cyclic GMP was
measured by EIA. In ventricular preparations, ANP or BNP
displayed no impact on 5-HT4-mediated inotropic response.
However, CNP increased the 5-HT4-mediated inotropic
response as well as the β1-adrenoceptor (β1-AR)-mediated
responsetoasimilarextentasPDE3inhibitionbycilostamide.
Pretreatment with cilostamide eliminated the effect of CNP.
Inhibition of nitric oxide (NO) synthase and soluble GC
by L-NAME and ODQ, respectively, attenuated the 5-HT4-
mediated inotropic response, whereas the NO donor Sin-1
increased this response. The effects were absent during
PDE3 inhibition, suggesting cGMP-dependent inhibition of
PDE3. However, in contrast to the effects on the 5-HT4
response, Sin-1 inhibited whereas L-NAME and ODQ
enhanced the β1-AR-mediated inotropic response. cGMP
generated both by particulate (NPR-B) and soluble GC
increases the 5-HT4-mediated inotropic response in failing
hearts, probably through inhibition of PDE3. β1-AR and 5-
HT4 receptor signalling are subject to opposite regulatory
control by cGMP generated by soluble GC in failing hearts.
Thus, cGMP from different sources is functionally compart-
mented, giving differential regulation of different Gs-coupled
receptors.
Keywords Natriuretic peptides.Phosphodiesterases.
5-HT4 receptors.Heart failure.Cyclic nucleotides.
Compartmentation
Introduction
The failing human and rat cardiac ventricles, regardless of
heart failure aetiology, become sensitive to serotonin (5-HT)
which elicits a positiveinotropic responsethroughstimulation
of 5-HT4 receptors (Brattelid et al. 2004, 2007; Qvigstad et
al. 2005). 5-HT4 receptors are Gs-coupled, and their positive
inotropic and lusitropic effects are assumed to be mediated
by cAMP both in rat and human myocardium (Kaumann and
Levy 2006; Afzal et al. 2008; Qvigstad et al. 2005; Gergs et
al. 2009) in similarity with β-adrenoceptors (β-ARs)
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DOI 10.1007/s00210-011-0670-6(Brodde and Michel 1999). Stimulation of β-ARs is
increased in heart failure, and chronic stimulation is
considered deleterious for the failing heart due to elevated
levels of cAMP that activates processes leading to increased
energy expenditure and calcium overload (Lohse et al. 2003).
Accordingly, in line with treatment with β-AR antagonists
(β-blockers), treatment with a 5-HT4 receptor antagonist has
shown beneficial effects in rats with heart failure (Birkeland
et al. 2007). Moreover, treatment with piboserod, a 5-HT4
receptor antagonist, has been shown to increase left
ventricular ejection fraction in patients with heart failure
(Kjekshus et al. 2009).
Cyclic GMP (cGMP) is a cyclic nucleotide synthesized
by guanylyl cyclase (GC) and activates cGMP-dependent
protein kinase (PKG), which mediates a series of cardiac
effects such as metabolic responses and modulation of
cardiac contractility (Shah and MacCarthy 2000). Two
types of GC exist, differing in cellular localization and
activation by specific ligands. Particulate GC (pGC) is
located in the plasma membrane as an integral part of the A
and B type natriuretic peptide receptors (NPRs) and is
activated by these peptides (Kuhn 2003), whereas soluble
GC (sGC) is present in cytosol and is activated by nitric
oxide (NO) (Kuhn 2003). Atrial (ANP) and brain (BNP)
natriuretic peptides mediate their effects by binding to and
activation of the cell surface GC natriuretic peptide receptor
A (NPR-A), whereas CNP activates the B-type natriuretic
peptide receptor (NPR-B) (Kuhn 2003). Plasma levels of
ANP, BNP and CNP produced by the myocardium are
increased in heart failure (Kalra et al. 2003; Mukoyama et
al. 1991). It is well known that NO, which is traditionally
known as a vasodilator, also affects myocardial function
and modulates cardiac excitation–contraction coupling in
multifaceted ways (Massion et al. 2003). The NO-
dependent signalling attenuates β-adrenergic responses,
and the activity of myocardial NO synthase (NOS) is
reported to be enhanced in heart failure (Bendall et al.
2004; Damy et al. 2003, 2004; Layland et al. 2002). As
both natriuretic peptides and NO are increased in heart
failure, their increased local effects may increase cGMP
levels within the cardiac tissue. We recently found that both
BNP and CNP increased cGMP in isolated cardiomyocytes
from rat failing hearts (Qvigstad et al. 2010). Thus, both
NPR-A and NPR-B receptors are operative in failing
cardiomyocytes.
Cyclic nucleotide phosphodiesterases (PDEs) are the only
enzymes that degrade cyclic nucleotides (cAMP or cGMP)
and thus play crucial roles in regulating the amplitude,
duration and localization of cyclic nucleotide signalling
(Fischmeister et al. 2006). Cyclic GMP-dependent signalling
may cross-talk with cAMP-dependent signalling, as varying
concentrations of cGMP can regulate the activity of PDEs
hydrolyzing cAMP and thus alter the concentration of cAMP
andhencethedownstreamsignalling(ZaccoloandMovsesian
2007). We have previously reported that, in failing cardiac
ventricles, PDE3 is the major PDE isoform regulating the
inotropic responses to β-ARs (Afzal et al. 2011)a n d5 - H T 4
receptors (Afzal et al. 2008). However, a role of PDE4 is
demasked when PDE3 is already inhibited. PDE3 can
degrade both cAMP and cGMP but has a lower enzymatic
activity towards cGMP, and increasing concentrations of
cGMPeffectivelyinhibitthedegradationof cAMP(Degerman
et al. 1997). We thus investigated whether agents increasing
cGMP would amplify the responses to 5-HT4 receptor
stimulation in failing myocardium.
Accordingly, the aims of this study were to evaluate the
regulatory effects of increased cGMP levels generated by
pGC and sGC, respectively, to elucidate whether separate
functional cGMP pools might exist. Thus, we studied the
functional influences of natriuretic peptides through pGC
and NO-dependent signalling through sGC on the 5-HT4-
elicited positive inotropic response in failing rat ventricle.
We show that CNP, but not ANP or BNP, increases the 5-
HT4-elicited positive inotropic response through inhibition
of PDE3, probably exerted by a localized pool of cGMP.
Moreover, cGMP generated by NO/sGC increases the 5-
HT4-mediated inotropic response, most likely by inhibiting
PDE3. This was in striking contrast to the β1-AR-mediated
inotropic response, which was attenuated by stimulation of
sGC.
Methods
Animal model
Animal care was according to the Norwegian Animal
Welfare Act, which conforms to the Guide for the Care
and Use of Laboratory Animals as adopted and promulgated
by the US National Institutes of Health, and was approved by
the Norwegian Animal Research Authority. As described, an
extensive myocardial infarction was induced in 320-g male
Wistar rats by coronary artery ligation for 6 weeks. Left
ventricular end diastolic pressures (LVEDP) were measured
bycatheterizationasdescribedearlier(Sjaastadetal.2003). In
order to obtain well-characterized heart failure, rats were
only included in the study when the infarct size was larger
than 30% of the left ventricular inner surface and the LVEDP
was 15 mmHg or higher after 6 weeks (HF) (Sjaastad et al.
2000).
Papillary muscles/ventricular strips
Left ventricular papillary muscles and ventricular strips
were prepared and mounted in organ baths (31°C) with a
physiological salt solution with a Ca
2+ concentration of
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(Sjaastad et al. 2003). The contraction–relaxation cycles
(CRC) were recorded and analyzed as described previously
(Sjaastad et al. 2003) with respect to maximal developed
force (Fmax, millinewton) and maximal development of
force ((dF/dt)max). The (dF/dt)max was used as an index of
contractility, and inotropic response to agonists was
expressed as increases in (dF/dt)max in percentage of
control levels. Blockers of α1-adrenoceptors (prazosin
1 μM), β-adrenoceptors (timolol 1 μM, except the experi-
ments with (−)-noradrenaline), muscarinic cholinergic
receptors (atropine 1 μM) and 5-HT2A receptors (ketanserin
0.1 μM) were added 90 min before the agonists in order to
obtain selective receptor stimulation and to avoid possible
indirect effects by release of endogenous substances. PDE3
inhibitor (cilostamide 1 μM), PDE4 inhibitor (rolipram
10 μM), NO-synthase inhibitor (L-NAME 100 μM) and
sGC inhibitor (ODQ 10 μM) were added as specified
45 min before the agonists. The NO donor (Sin-1 300 μM),
ANP (1 μM), BNP (1 μM) and CNP (300 nM) were added
20 min before the agonist as specified. These drugs did not
influence the basal CRC characteristics or electrical
stimulation threshold (data not shown), except 300 nM
CNP, which reduced the basal (dF/dt)max by 12.5±1.3% (n=
19). (−)-Noradrenaline in the presence of 50 nM ICI118551
(and 1 μM prazosin) was used to selectively stimulate β1-
ARs. 5-HT or (−)-noradrenaline was added to the organ bath
cumulatively (concentration–response relationship). Concen-
tration–response curves were constructed by estimating
centiles (EC10 to EC100) and calculating the corresponding
means and the horizontal positioning expressed as –logEC50
(Sjaastad et al. 2003). Compared to stimulation of β1-ARs,
stimulation of 5-HT4 receptors in failing myocardium with 5-
HT gives a lower inotropic response. Therefore, comparable
to the behaviour of a partial agonist, any enhancement of the
response increases the maximal response (efficacy) and not
necessarily the potency (Afzal et al. 2008). Thus, in order to
visualize the effect of any intervention, the concentration–
response curves of 5-HT are plotted as percent above basal.
In contrast, the concentration–response curves of the “full
agonist” (−)-noradrenaline are normalized to the individual
maxima, as any enhancement of the response increases
the sensitivity (lowers EC50) of the response without any
significant change in the efficacy. However, the individual
maximal values of inotropic responses to both 5-HT and (−)-
noradrenaline are presented in Tables 2 and 3. Since the
inotropic response to 5-HT4 stimulation induced during heart
failure is remarkably reproducible in papillary muscles, these
muscles were reserved for these studies. The inotropic
response to noradrenaline, however, always appears as full
agonism, and as changes in EC50 will not be influenced by
random variation in maxima, ventricular strips could
accordingly be used for these studies. Therefore, left
ventricular papillary muscles were used in experiments with
5-HT, and left ventricular strips were used in experiments
with (−)-noradrenaline.
cGMP content in left ventricular strips
Left ventricular strips (described above) were equilibrated for
90 min and freeze-clamped 45 min after addition of ODQ
(inhibitor of sGC) or L-NAME (NO synthase inhibitor) and
20 min after Sin-1 (NO donor). Frozen tissue was homoge-
nized at 4°C in 1 ml 5% trichloroacetic acid by a Retch
MM301 mechanical mill. Total cGMP levels were measured
by cGMP EIA kit (Cayman Chemicals) according to the
manufacturer's protocol.
Materials
5-HT hydrochloride, (−)-Arterenol ([−]-noradrenaline)
bitartrate (hydrate), timolol maleate, prazosine hydrochloride
and atropine sulphate were purchased from Sigma-Aldrich
(St. Louis, MO, USA). Rolipram (4-(3-(cyclopentyloxy)-4-
methoxyphenyl)pyrrolidin-2-one), cilostamide (N-cyclo-
hexyl-N-methyl-4-(1,2-dihydro-2-oxo-6-quinolyloxy)butyra-
mide), Sin-1 (amino-3-morpholinyl-1,2,3-oxadiazolium)
chloride, ICI118551 ((±)-erythro-(S*,S*)-1-[2,3-(dihydro-7-
methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-bu-
tanol) hydrochloride, ODQ (1H-[1,2,4]oxadiazolo[4,3-a]qui-
noxalin-1-one), L-NAME (NG-Nitro-L-arginine methyl ester)
hydrochloride and ketanserin (3-[2-[4-(4-fluorobenzoyl)-1-
piperidinyl]ethyl]-2,4[1H,3 H]-quinazolinedione) tartrate
were from Tocris Bioscience (Bristol, UK). Isoflurane
(Forene) was from Abbot Scandinavia (Solna, Sweden).
Statistics
All results are expressed as mean±SEM unless otherwise
indicated, and statistical significance was assessed with
Table 1 Animal characteristics
HF-rats (n=151)
Body weight, g 359±3.3
Heart weight, g 2.5±0.3
Heart weight/body weight, g kg
−1 6.5±0.1
LVEDP, mmHg 22.8±0.4
LVSP, mmHg 100.6±1.4
Lung weight, g 3.7±1.1
Basal Fmax/CSA, mN/mm
2 5.4±0.2
HF post-infarction heart failure, LVEDP left ventricular end-diastolic
pressure, LVSP left ventricular systolic pressure, HF-rats rats with
myocardial infarction larger than 30% of inner surface area, Fmax/CSA
maximal developed force per cross-sectional area of the contracting
papillary muscles (mean±SEM)
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appropriate, Bonferroni corrections were made. p<0.05 was
regarded to reflect statistically significant differences.
Results
All the rats included in the study had anterolateral infarcts
larger than 30% of the left ventricular inner surface, LVEDP
>15 mmHg at 6 weeks and signs of HF, including
tachypnoea and pulmonary congestion. For animal charac-
teristics and haemodynamic data, see Table 1. For simpli-
fication and in order to prompt direct comparison between
the different experiments, the data from the concentration–
response curves (discussed below) are listed in Tables 2 and
3 in addition to the presentation in the figures.
Effect of natriuretic peptides on the 5-HT4-elicited inotropic
response
CNP and not ANP or BNP increases the 5-HT4-elicited
inotropic response
We have previously demonstrated that both NPR-A and
NPR-B receptors are operative in both cardiomyocytes and
ventricular strips from failing rat ventricles, as both BNP
Table 2 The maximal inotropic response (dF/dt)max in percent above basal (100%) and –logEC50 values (pEC50) of the concentration–response
curves in the different experimental groups that are illustrated in Figs. 1 and 2
5-HT4/NP β1-AR/NP
(dF/dt)max (% above basal) pEC50 n (dF/dt)max (% above basal) pEC50 n
Control 21.1±3.0 7.32±0.08 7 72.8±7.3 6.65±0.07 8
ANP 24.5±4.9 7.38±0.07 4
BNP 20.5±3.9 7.53±0.09 5
CNP 41.3±3.8 7.29±0.09 12 74.9±10.4 7.21±0.11 7
Cil 49.7±6.5 7.30±0.10 7
Rol 86.8±14.0 6.77±0.12 10
Cil/Rol 67.8±5.1 7.96±0.11 7
Cil/CNP 50.0±6.0 7.55±0.11 6 85.3±16.1 7.09±0.08 7
Rol/CNP 65.1±8.6 7.95±0.13 6 77.2±7.3 7.73±0.06 7
Note that the maximal inotropic response of β1-ARs is presented as absolute maximal response in the table, whereas in Fig. 2, they are presented
normalized to their maxima. For statistical analyses, please confer to the respective figures. 5-HT4/NP and β1-AR/NP, concentration–response
curves performed mainly to study the effect of the natriuretic peptides (NP)/pGC on responses mediated via 5-HT4 receptors and β1-ARs,
respectively. Mean±SEM of n experiments
Table 3 The maximal inotropic response (dF/dt)max in percent above basal (100%) and –logEC50 values (pEC50) of the concentration–response
curves in the different experimental groups that are illustrated in Figs. 4 and 5
5-HT4/NO β1-AR/NO
(dF/dt)max (% above basal) pEC50 n (dF/dt)max (% above basal) pEC50 n
Control 23.0±2.7 7.39±0.07 11 82.1±3.1 6.69±0.02 7
Sin-1 32.9±3.2 7.00±0.10 6 90.9±13.6 6.23±0.03 6
L-NAME 8.6±1.5 7.34±0.09 8 77.3±10.5 7.16±0.10 6
ODQ 13.5±2.3 7.36±0.07 10 78.8±9.8 7.30±0.15 6
Cil/L-NAME 47.7±7.8 7.53±0.09 6
Cil/Sin-1 49.3±3.7 7.44±0.11 10
Rol/Sin-1 43.0±3.5 7.16±0.11 7
Cil/Rol/L-NAME 66.9±8.2 7.87±0.16 6
Note that the maximal inotropic response of β1-ARs is presented as absolute maximal response in the table, whereas in Fig. 4, they are presented
normalized to their maxima. For statistical analyses, please confer to the respective figures. 5-HT4/NO and β1-AR/NO, concentration–response
curves performed mainly to study the effect of the nitric oxide (NO)/sGC system on responses mediated via 5-HT4 receptors and β1-ARs,
respectively. Mean±SEM of n experiments
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determined the effect of ANP, BNP and CNP on 5-HT4-
mediated inotropic response in papillary muscles from
failing rat left ventricles. Stimulation of NPR-A by 1 μM
ANP or 1 μM BNP did not change the responsiveness to 5-
HT (Fig. 1). However, stimulation of NPR-B by 300 nM
CNP significantly increased the inotropic response to 5-HT
compared to control (Figs. 1 and 2a).
CNP increases the 5-HT4-elicited inotropic response
through inhibition of PDE3
Despite the increase in the responsiveness, there was no
change in the sensitivity to 5-HT (EC50) in the presence
of CNP compared to control (Fig. 2a). During PDE4
inhibition (10 μM rolipram) in the presence of 300 nM
CNP, there was a significant increase in both the
responsiveness and the sensitivity to 5-HT compared to
the presence of CNP alone (Fig. 2a). Similar patterns were
observed during PDE3 inhibition alone (1 μM cilosta-
mide) and during concomitant PDE3/4 inhibition
(Fig. 2a), consistent with our previous report that PDE3
inhibition enhances the inotropic response to 5-HT and
concomitant PDE3 and PDE4 inhibition further enhances
the responsiveness and also enhances the sensitivity to 5-
HTcompared to PDE3 inhibition alone (Afzal et al. 2008).
To evaluate whether CNP enhanced the 5-HT4-mediated
inotropic response through inhibition of PDE3, we tested
the effect of CNP (300 nM) in the presence of cilostamide
(1 μM). Preincubation with both cilostamide and CNP
simultaneously did not significantly further increase the
inotropic response to 5-HT compared to CNP or cilosta-
mide alone, consistent with a PDE3-dependent mechanism
of CNP (Fig. 2a).
Fig. 2 a Concentration–response curves of inotropic responses to 5-
HT4 receptor stimulation in papillary muscles in the absence (control)
or presence of 300 nM CNP or in combination with PDE inhibitors
(Cil,1μM cilostamide; Rol,1 0μM rolipram). b Concentration–
response curves of inotropic responses (normalized) to β1-adrenocep-
tor stimulation by (−)-noradrenaline (50 nM ICI118551 present) in
absence (control) or presence of CNP or in combination with PDE
inhibitors (Cil,1μM cilostamide; Rol,1 0μM rolipram) in left
ventricular strips. CNP and PDE inhibitors were added 20 and 45 min
before the agonist, respectively. Ordinate: inotropic response expressed
as increase in (dF/dt)max in percent above basal (a)o ra sp e r c e n to f
maximum (normalized) (b). Vertical bars represent SEM of maximal
inotropic responses. Abscissa: concentration of the agonist. Horizontal
bars represent SEM of –logEC50. Double asterisks: p<0.01 CNP vs.
control (for maximal response in a,a n d–logEC50 in b). Single crosses:
p<0.01 CNP/Rol vs. CNP (for maximal response in a,a n d–logEC50 in
b). Double crosses: p<0.01 –logEC50 CNP/Rol vs. CNP
Fig. 1 Concentration–response curves of inotropic responses to 5-
HT4 receptor stimulation in the absence (control) or presence of
natriuretic peptides; 1 μM ANP, 1 μM BNP or 300 nM CNP.
Natriuretic peptides were added 20 min before 5-HT. Ordinate:
inotropic response expressed as increase in (dF/dt)max in percent
above basal. Vertical bars represent SEM of maximal inotropic
responses. Abscissa: concentration of the agonist. Horizontal bars
represent SEM of –logEC50. Double asterisks: p<0.01 vs. control
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through PDE3 inhibition
In order to perform a direct comparison with the modulation
of 5-HT4-mediated response, we also tested the effect of
CNP on the β1-AR-mediated inotropic response in the
present study. In accordance with our previous report
(Qvigstad et al. 2010), 300 nM CNP sensitized the β1-AR-
mediated inotropic response, with a further increase in
sensitivity during concomitant PDE4 inhibition with
10 μMr o l i p r a m( F i g .2b). Moreover, additional presence of
1 μM cilostamide did not further sensitize the β1-mediated
inotropic response compared to CNP alone (Fig. 2b),
consistent with CNP increasing the β1-AR-mediated inotro-
pic response through PDE3 inhibition (Qvigstad et al. 2010).
Effect of endogenous nitric oxide on the 5-HT4-elicited
inotropic response
NO increases the 5-HT4-elicited inotropic response
The NO-dependent signalling is increased in heart failure
and thus the cGMP levels. As increase in cGMP levels by
pGC enhances the 5-HT4-elicited inotropic response, we
determined the effect of cGMP generated by sGC on the
inotropic response to 5-HT. Inhibition of NOS (100 μM
L-NAME) decreased both the cGMP levels (Fig. 3)a n dt h e
inotropic response to 5-HT (Fig. 4a). Inhibition of sGC
(10 μM ODQ) nominally decreased the cGMP levels without
reachingstatisticalsignificancebut significantlydecreasedthe
inotropic response to 5-HT. Thus, both approaches indicate
that endogenous NO contributes to increase the 5-HT4-
mediated inotropic response in the failing ventricle, as
inhibition of the NO pathway decreases the response. In
addition, the NO donor Sin-1 (300 μM) increased the cGMP
levels (Fig. 3) and also nominally increased the inotropic
response to 5-HT (Fig. 4a), although without reaching
statistical significance (p=0.08 after Bonferroni correction).
NO increases the 5-HT4-elicited inotropic response
presumably through PDE3 inhibition
To determine whether cGMP generated by the sGC increased
the 5-HT4-mediated inotropic response through inhibition of
Fig. 3 Cyclic GMP levels in left ventricular strips in absence
(control) or presence of 100 μM L-NAME (NOS inhibitor), 10 μM
ODQ (sGC inhibitor) or 300 μM Sin-1 (NO donor). L-NAME and
ODQ were added 45 min before and Sin-1 20 min before the
ventricular strips were snap-frozen. Number of experiments “n” inside
the bars; mean±SEM. Asterisk: p<0.05 vs. control. Number sign: p=
0.16 vs. control (after Bonferroni correction)
Fig. 4 a, b Concentration–response curves of inotropic responses to
5-HT4 receptor stimulation in the absence (control) and presence of
100 μM L-NAME (NOS inhibitor), 10 μM ODQ (sGC inhibitor),
300 μM Sin-1 (NO donor) or in combination with PDE inhibitors (Cil,
1 μM cilostamide; Rol,1 0μM rolipram) in papillary muscles. All the
inhibitors were added 45 min before 5-HT, whereas Sin-1 was added
20 min before 5-HT. Ordinate: inotropic response expressed as
increase in (dF/dt)max in percent above basal. Vertical bars represent
SEM of inotropic response. Abscissa: concentration of the agonist.
Horizontal bars represent SEM of –logEC50. Asterisk: p<0.05 vs.
control. Number sign: p=0.08 vs. control (after Bonferroni correction)
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in the presence of 100 μM L-NAME or 300 μMS i n - 1i n
papillary muscles preincubated with 1 μM cilostamide.
During this PDE3 inhibition, intervention with NO signalling
by L-NAME or Sin-1 did not exhibit any additional effect on
the 5-HT4-mediated inotropic response compared to PDE3
inhibition alone, suggesting that PDE3 is inhibited by NO-
generated cGMP (Fig. 4b). Accordingly, during combined
PDE3/4 inhibition, there was no difference between the
absence or presence of 100 μM L-NAME (Fig. 4b). Addi-
tionally, during PDE4 inhibition, 300 μM Sin-1 significantly
increased the inotropic response to 5-HTcompared to control
(Fig. 4a), thus providing a more substantial effect than
300 μM Sin-1 alone, which only nominally increased the
inotropic response compared to control. These results suggest
that the increased NO signalling here most likely acts through
inhibition of PDE3 due to the increased cGMP levels.
NO decreases the β1-AR-mediated inotropic response
For comparison, wedetermined the effect of increased (Sin-1)
and decreased (L-NAME, ODQ) NO signalling on the β1-
AR-mediated inotropic response. Sin-1 decreased, whereas
L-NAME and ODQ increased the sensitivity of the β1-AR-
mediated inotropic response (Fig. 5). These results are
contrary to those on the 5-HT4-elicited inotropic response,
but in accordance with previous reports that NO signalling
decreases β1-adrenergic signalling (Bendall et al. 2004;
Damy et al. 2003, 2004).
Discussion and conclusions
We demonstrate here that the stimulation of NPR-B by CNP
increases the 5-HT4-mediated inotropic response in failing
rat heart ventricles. This effect is most likely caused by
cGMP-mediated PDE3 inhibition, as the PDE3 inhibitor
cilostamide increased the response to a similar extent as
CNP without any additive effect. Similar results were
obtained for the β1-AR-mediated inotropic response both in
this study and previously (Qvigstad et al. 2010). We also
presently demonstrate that stimulation of NPR-A by ANP or
BNP does not affect the 5-HT4-mediated inotropic response,
which is in line with the previously reported lack of effect on
the β1-AR-mediated inotropic response (Qvigstad et al.
2010). These differences between stimulation of NPR-B
and NPR-A are quite remarkable, as both receptors increase
cGMP levels in isolated cardiomyocytes from failing hearts
(Qvigstad et al. 2010). Thus, these results suggest the two
NPRs generate different cGMP pools, only one of which is
available to the PDE3 regulating cAMP-mediated intropic
response. We also demonstrate that cyclic GMP generated by
sGC enhances the 5-HT4-mediated inotropic response by
PDE3 inhibition. This is in contrast to the β1-AR-mediated
inotropic response, which is inhibited by increased cGMP
levels produced by NO-stimulated sGC. The divergent
influence of cGMP generated from sGC on these different
Gs-coupled receptor systems suggests both different compart-
ments within this cGMP pool and separate compartments for
5-HT4 receptor- and β1-AR-mediated signalling pathways.
Amplification of 5-HT4-mediated inotropic response
by CNP
NPR-B stimulation by CNP increased the 5-HT4-mediated
inotropic response to a similar extent as the PDE3 inhibitor
cilostamide, and additional PDE3 inhibition did not promote
any further increase. This is consistent with inhibition of
PDE3 by cGMP generated following stimulation by CNP.
Furthermore, this was substantiated by the observation that in
the presence of PDE4 inhibition by rolipram, the effect of
CNP on the inotropic response was further enhanced to a
similar level as by concomitant PDE3/4 inhibition, i.e. an
increase in the maximal response accompanied by a sensiti-
zation of the inotropic response, as the role of PDE4 is
demasked by inhibition of PDE3 (Afzal et al. 2008, 2011).
Similarly, we demonstrated that the β1-AR-mediated inotro-
pic response is also enhanced by CNP. This is in accordance
Fig. 5 Concentration–response curves of inotropic responses (nor-
malized) to β1-adrenoceptor stimulation by (−)-noradrenaline (50 nM
ICI118551 present) in absence (control) or presence of 100 μM L-
NAME (NOS inhibitor), 10 μM ODQ (sGC inhibitor) or 300 μM Sin-
1 (NO donor) in left ventricular strips. L-NAME and ODQ were added
45 min before and Sin-1 20 min before the (−)-noradrenaline.
Ordinate: inotropic response expressed as increase in (dF/dt)max in
percent of maximum (normalized). Abscissa: concentration of the
agonist. Horizontal bars represent SEM of –logEC50. Double asterisks:
p<0.01 vs. control
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showing that β1-AR-mediated inotropic response is en-
hanced by CNP, most likely due to PDE3 inhibition, and
that CNP stimulation increased the cAMP levels during β1-
AR-activation to similar levels as cilostamide. Wen et al.
(2004) found that CNP, by activating pGC, increased cAMP
accumulation by inhibiting PDE3 in rabbit atria. In line with
this, our functional data support a profound inhibition of
PDE3 by cGMP generated in response to NPR-B activation
by CNP in failing rat ventricle. Moreover, a recent study has
shown that in hypertrophic human ventricle, the balance
of effects of activating the cGMP-PKG pathway is shifted
from effects of PKG activation towards effects of PDE3
inhibition, due to decreased PKG activity (Nagendran et al.
2007).
Amplification of the 5-HT4-mediated inotropic response
by sGC-generated cGMP
The activity of NOS isreported to be increasedin experimental
and human heart failure (Damy et al. 2003, 2004). We found
that inhibitors of NOS (L-NAME) and sGC (ODQ) decreased
the cGMP levels in ventricular strips, indicating a certain
endogenous NOS activity. This also makes it probable that
the observed effects in the presence of these inhibitors can be
ascribed to decrease in cGMP levels. Inhibition of NO
signalling by L-NAME and ODQ attenuated the 5-HT4-
mediated inotropic response, indicating that endogenous NO
contributes to increase the 5-HT4-mediated inotropic response
in failing hearts. Moreover, the NO donor Sin-1 increased
cGMP levels as well as the 5-HT4-mediated inotropic
response, suggesting that increasing the cGMP levels by
sGC activation increases the 5-HT4-mediated response.
During PDE3 inhibition by cilostamide, none of the effects
of L-NAME, ODQ and Sin-1 on the 5-HT4-mediated
response were observed, and the inotropic responses were
similar to those in the presence of PDE3 inhibition alone.
This indicates that increased response to cGMP is most likely
attributable to inhibition of PDE3, as when PDE3 is already
inhibited, no additional inhibition by cGMP is achievable.
This was also supported by the observation that during PDE4
inhibition by rolipram, Sin-1-dependent increase of 5-HT4-
mediated inotropic response with respect to control was larger
compared to that in the absence of PDE4 inhibition (Fig. 4a).
These results are in accordance with a previous study
showing that NO stimulates Ca
2+ channel current in human
atrial myocytes by inhibiting PDE3, and the stimulatory effect
o fS i n - 1o nC a
2+ channel current was masked in the presence
of the PDE3 inhibitor milrinone (Kirstein et al. 1995).
Interestingly, Sin-1 and rolipram in combination only
increased the maximal inotropic response without an increase
in the sensitivity of the response (Fig. 4a). This is in contrast
to concomitant inhibition of PDE3/4 with PDE3 inhibited by
either cilostamide or CNP, where there is also an increase in
the sensitivity (Fig. 2a), which reflects a full activation of the
cAMP-dependent signalling (Afzal et al. 2008). Possible
explanations for the lacking increase in the sensitivity of
inotropic response in the presence of Sin-1 and rolipram
mightbethatcomparedtoβ-AR-mediatedinotropicresponse,
the inotropic response to 5-HT4 receptor stimulation is
submaximal (Afzal et al. 2008), and Sin-1 is causing a less
efficient PDE3 inhibition than cilostamide and CNP. This is
supported by a lower maximal inotropic effect of 5-HT in the
presence of Sin-1/rolipram than in the presence of cilosta-
mide/rolipram or CNP/rolipram. This amplification of the 5-
HT4-mediated inotropic effect by NO signalling is in marked
contrast to the inhibitory effect on the β1-AR-mediated
inotropic response, as also confirmed in the present
study. The proposed mechanism for this attenuation of β-
AR-mediated inotropic response is PKG-dependent inhi-
bition of L-type Ca
2+ channels and subsequent suppres-
sion of β-adrenergic inotropic effect (Wang et al. 2009).
Moreover, PKG-dependent phosphorylation of troponin I
may also contribute to attenuate the β-adrenergic response
(Layland et al. 2002).
Evidence for compartmented cGMP pools
The present study provides some functional evidence for
apparently four compartmented cGMP pools in rat failing
myocardium by exploring the influence of different agents
increasing cGMP on the inotropic effects of the two Gs-
coupled receptors 5-HT4 and β1-AR, respectively (Fig. 6):
(1) cGMP generated by NPR-B enhancing the response to
both Gs-coupled receptors, probably by inhibiting PDE3;
(2) cGMP generated by NPR-A with no influence on either
of the two Gs-coupled receptors; (3) a pool of cGMP
generated by sGC enhancing the response to 5-HT4 only,
probably by inhibiting PDE3; and (4) a pool of cGMP
generated by sGC attenuating the response to β1-AR. Our
results showing that NO inhibits β-adrenergic signalling are
in line with previous studies by others (Bendall et al. 2004;
Damy et al. 2003; Layland et al. 2002). The opposite
influence of the NO system on 5-HT4 and β1-AR-mediated
effects illustrates a major qualitative difference between the
signalling of these two Gs-coupled receptors, which
otherwise possess distinct similarities. The findings suggest
a differential compartmented localization of 5-HT4 and β1-
AR and indicate a highly selective and intricate regulation
of inotropic responses mediated by Gs-coupled receptors.
This is further illustrated by similar effects of pGC-
generated cGMP on β1-ARs and 5-HT4 receptors in spite
of opposing effects on the receptors by sGC-generated
cGMP. These observations together provide evidence of an
intricate compartmentation of different cGMP pools affecting
the downstream signalling of different receptors in similar or
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unable to influence the response to the Gs-coupled receptors
studied remains obscure. A recent study has shown
differential effects of cGMP on cAMP levels via different
PDEs in spatially distinct subcellular domains (Stangherlin et
al. 2011). Other studies have also reported observations
indicating compartmented signalling of cGMP, depending on
the source of cGMP. ANP-stimulated cGMP displayed no
impact on β-AR-stimulated contractility in either the
presence or absence of PDE5 inhibitor, whereas NO-
stimulated cGMP elevation reduced the β-AR-stimulated
contractility, and the effect was enhanced during PDE5
inhibition (Takimoto et al. 2007). Moreover, the same study
showed that ANP-stimulated pGC did not activate PKG
despite substantial increase in cGMP levels, whereas PDE5
inhibition efficiently activated PKG. A study in mouse
cardiomyocytes showed that stimulation of both pGC and
sGC exerted similar negative inotropic response by cGMP-
dependent pathways, but only pGC activation reduced Ca
2+
transients, whereas sGC activation had only marginal effects
(Su et al. 2005). Other studies showed that the particulate
cGMP pool is controlled by PDE2, whereas the soluble
cGMP pool is controlled by PDE5, and the differential
cardiac effects of the cGMP were attributable to different
spatiotemporal distribution (Castro et al. 2006).
The cAMP signals generated by different Gs-protein-
coupled receptors in cardiomyocytes and controlled by
PDEs are known to be compartmented (Rochais et al. 2006;
Galindo-Tovar et al. 2009). As the cGMP-dependent path-
ways are able to cross-talk with cAMP-dependent pathways
and as different cross-talk mechanisms are operating,
discrepancy between the influence on the function of
receptors is not unexpected. To elucidate mechanisms
involved, it would be useful to determine the cAMP levels
under different experimental conditions and relate them to
contractile responses. However, based on our experience
(Afzal et al. 2008, 2011), the interpretation of such
measurements in ex vivo whole-tissue preparation is
complex, i.e. immeasurable cAMP increase may be
associated with clear functional amplification, and a marked
cAMP increase may appear without functional enhance-
ment. In order to understand these mechanisms, use of
selective FRET-based sensors with the ability to measure
cAMP or cGMP in distinct compartments would be a more
reasonable approach. Compartmentations may rely on
different locations of the receptors in the membrane, the
involved cyclases, the cyclic nucleotide PDEs and protein
kinases with their respective targets. Such phenomena may
occur within each cardiomyocyte and/or between cardio-
myocytes. Presently, a further elaboration of the concept of
compartmentation would require methods that identify the
relative location of the components involved in the
signalling pathways in the myocytes as well as their mutual
and dynamic interaction with each other.
Fig. 6 Illustration of the proposed functional compartmentation of 5-
HT4 receptor, β1-adrenoceptor and cyclic nucleotides in cardiac
myocytes. The inotropic response to 5-HT4 receptor and β1-
adrenoceptor stimulation is mediated by cAMP and regulated by
PDE3. 1: cGMP generated by NPR-B inhibits PDE3 and increases the
5-HT4 receptor- and β1-adrenoceptor-mediated inotropic response. 2:
cGMP generated by NPR-A has no access to the PDE3 regulating
inotropic response. 3: A pool of cGMP generated by sGC increases
the 5-HT4-mediated inotropic response by inhibiting PDE3. 4: A pool
of cGMP generated by sGC has no access to the PDE3 regulating the
β1-adrenoceptor-mediated inotropic response, but inhibits it by some
other mechanism, possibly through PKG
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effects in failing myocardium
We have shown that both BNP and CNP elicited a robust
increase in cGMP levels in ventricular tissue and cardiomyo-
cytes from failing hearts (Qvigstad et al. 2010). Moreover,
ANP also profoundly increased the cGMP levels in myocar-
dial tissue (Takimoto et al. 2007). Despite the increase in
cGMP levels by both NPR-A and NPR-B, only NPR-B-
mediated increases in cGMP levels enhance the 5-HT4
receptor and β1-AR-mediated inotropic responses in failing
rat ventricles, indicating that NPR-B might play a more
prominent role in regulating the cardiac contractility in heart
failure. This is supported by another study which reported
increased activity of NPR-B compared to NPR-A, and thus a
more dominant role of NPR-B than NPR-A receptors in
failing mouse hearts compared to Sham hearts (Dickey et al.
2007). Moreover, in the absence of NPR-A in genetic mouse
models, the contractile responses to CNP activating NPR-B
were enhanced compared to mice expressing NPR-A (Pierkes
et al. 2002), which might be similar to the situation in the
failing myocardium as described above. In heart failure, CNP
plasma levels show a significant increase which parallels
clinical severity and correlates negatively with indices of left
ventricular function such as ejection fraction and (dP/dt)max
(Del Ry et al. 2005, 2008). Activation of 5-HT4 receptors
elevates cAMP, and longstanding cAMP-dependent effects
are associated with deleterious cardiac effects (Lohse et al.
2003). 5-HT4 receptor stimulation may also promote
arrhythmia (Kaumann and Levy 2006). The increased levels
of CNP and increased NO signalling in heart failure might
contribute to accentuate these potentially harmful effects of
5-HT4 receptor activation in patients with heart failure.
Conclusions
Inconclusion,cGMPgeneratedbybothpGC,throughNPR-B,
and sGC increases the 5-HT4-mediated inotropic response.
This is in contrast to β1-ARs, where pGC-generated cGMP
(through NPR-B) increases the inotropic response, whereas
sGC-generated cGMP decreases the inotropic response.
These results provide evidence of distinctly different func-
tional cGMP pools regulating the inotropic response to
activation of different receptors depending on the source of
cGMP (Fig. 6). Compartmented localization of the Gs-
coupled receptors may also be involved in this differential
regulation of their function.
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